Social Support for People with Haemophilia
Social support for people with haemophilia in the Czech Republic: disability cards, care allowances, parking permits and disability pensions.
Overview of social support
People with disabilities, including those with haemophilia, may encounter various difficult social situations in life. The social protection system in the Czech Republic provides people with bleeding disorders a range of tools — from disability cards through care allowances to disability pensions. The scope of entitlements depends on the degree of disability and its impact on everyday life.
We have prepared a social essentials guide that should help you with basic orientation in common social situations — what you can apply for if needed, where to turn, and what you may need.
Disability card
The TP, ZTP or ZTP/P card is the basic document proving a disability. It entitles the holder to a number of benefits in transport, tax payments and other areas. The card is issued by the Labour Office of the Czech Republic based on an assessment by a medical examiner.
Benefits for persons with disabilities
People with disabilities can apply for a mobility allowance, a special aid allowance and other benefits. The amount and scope of benefits depends on the degree of disability and the individual needs of the applicant.
Parking permit
Holders of a ZTP or ZTP/P card are entitled to mark their vehicle with an O7 parking permit, which allows parking in reserved spaces and other traffic benefits.
Care allowance
The care allowance is intended for people who, due to a long-term unfavourable health condition, need the help of another person in managing basic life needs. It is granted at four levels of dependency.
Disability pensions
A disability pension may be received by people whose working capacity has decreased as a result of a health disability. Three degrees of disability are distinguished based on the degree of reduction in working capacity.
Further information
Related Articles
New Technologies in Treatment 2024
The first weekend of November is traditionally dedicated to a workshop on new technologies in treatment organized by the European Haemophilia Consortium (EHC).
Read more
Gene Therapy - A Practical Guide
We bring you a new publication—a translation of a practical guide on gene therapy published as part of the EHC’s editorial activities.
Read more
New Technologies in Treatment 2023
New developments in non-factor therapy, rebalancing therapy, gene therapy or artificial intelligence. These and other topics were discussed at the workshop on new technologies in the treatment of rare bleeding diseases, held in Lisbon, Portugal, November 3-5, 2023.
Read more
Advances in the Treatment of Hemophilia and von Willebrand Disease
From 11-13 November 2022, a workshop organized by the European Haemophilia Consortium took place in Marseille, France, focusing on new technologies in the treatment of hemophilia and other rare bleeding disorders. The Czech Hemophilia Society was represented on site by Vice-Chairman Martin Žídek and MUDr. Pavel Mazánek, who serves as Deputy Head of Haematology at the Department of Paediatric Haematology and Biochemistry at the University Hospital Brno.
Read more
Recommendations of the Czech National Hemophilia Program (CNHP) on Vaccination Against SARS-CoV-2
Recommendations on vaccination against SARS-CoV-2 (COVID-19) were published earlier this year in the journal Haemophilia, and a brief translation is available on our website at [this link](/novinky/prohlaseni-k-ockovani-proti-pandemii). The recommendations are endorsed by the World Federation of Hemophilia (WFH), the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), and the National Hemophilia Foundation of the United States (NHF). These recommendations, including their Czech translation, already contain all the essential information.
Read more
Statement on Pandemic Vaccination
Vaccination against COVID-19 is the most pressing topic of recent months. Statements have been issued by the World Federation of Hemophilia (WFH), the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), and the National Hemophilia Foundation of the United States (NHF). The statement applies to persons over 18 years of age; for younger individuals, we continue to monitor developments and studies.
Read more